IMMUPHARMA PLC LS-01
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company's lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lup… Read more
IMMUPHARMA PLC LS-01 (25I) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, IMMUPHARMA PLC LS-01 (25I) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
IMMUPHARMA PLC LS-01 - Net Assets Trend (None–None)
This chart illustrates how IMMUPHARMA PLC LS-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for IMMUPHARMA PLC LS-01 (None–None)
The table below shows the annual net assets of IMMUPHARMA PLC LS-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to IMMUPHARMA PLC LS-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
IMMUPHARMA PLC LS-01 Competitors by Market Cap
The table below lists competitors of IMMUPHARMA PLC LS-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Denali Bancorporation Inc
PINK:DENI
|
$28.39 Million |
|
METAIR INVTS LTD O.N.
F:M4HA
|
$28.39 Million |
|
Atlas Resources Tbk
JK:ARII
|
$28.40 Million |
|
Saultech Technology Co., Ltd
TWO:6812
|
$28.43 Million |
|
Service & Quality Technology Co Ltd
TWO:3219
|
$28.38 Million |
|
Dynamix Corporation Warrant
NASDAQ:DYNXW
|
$28.37 Million |
|
Soonest Express Co Ltd
TWO:2643
|
$28.36 Million |
|
Dsr Wire
KO:069730
|
$28.35 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IMMUPHARMA PLC LS-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares IMMUPHARMA PLC LS-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently IMMUPHARMA PLC LS-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares IMMUPHARMA PLC LS-01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IMMUPHARMA PLC LS-01 (25I) | €- | N/A | N/A | $28.38 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |